DOP2012000030A - Polipéptidos del factor ix modificados y usos de los mismos - Google Patents

Polipéptidos del factor ix modificados y usos de los mismos

Info

Publication number
DOP2012000030A
DOP2012000030A DO2012000030A DO2012000030A DOP2012000030A DO P2012000030 A DOP2012000030 A DO P2012000030A DO 2012000030 A DO2012000030 A DO 2012000030A DO 2012000030 A DO2012000030 A DO 2012000030A DO P2012000030 A DOP2012000030 A DO P2012000030A
Authority
DO
Dominican Republic
Prior art keywords
polipeptides
factor
same
modified factor
modified
Prior art date
Application number
DO2012000030A
Other languages
English (en)
Spanish (es)
Inventor
Chandra Patel
Xiaoqiao Jiang
Heiner Apeler
Jun Wang
Alan Brooks
Uwe Gritzan
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000030(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of DOP2012000030A publication Critical patent/DOP2012000030A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DO2012000030A 2009-07-31 2012-01-27 Polipéptidos del factor ix modificados y usos de los mismos DOP2012000030A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31

Publications (1)

Publication Number Publication Date
DOP2012000030A true DOP2012000030A (es) 2012-02-29

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000030A DOP2012000030A (es) 2009-07-31 2012-01-27 Polipéptidos del factor ix modificados y usos de los mismos

Country Status (21)

Country Link
US (1) US20120164130A1 (cg-RX-API-DMAC7.html)
EP (1) EP2461821A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013500726A (cg-RX-API-DMAC7.html)
KR (1) KR20120060209A (cg-RX-API-DMAC7.html)
CN (1) CN102573890A (cg-RX-API-DMAC7.html)
AU (1) AU2010278721A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012002072A2 (cg-RX-API-DMAC7.html)
CA (1) CA2769258A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012000238A1 (cg-RX-API-DMAC7.html)
CR (1) CR20120052A (cg-RX-API-DMAC7.html)
CU (3) CU20120018A7 (cg-RX-API-DMAC7.html)
DO (1) DOP2012000030A (cg-RX-API-DMAC7.html)
EA (1) EA201290069A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011637A (cg-RX-API-DMAC7.html)
GT (1) GT201200023A (cg-RX-API-DMAC7.html)
IN (1) IN2012DN00908A (cg-RX-API-DMAC7.html)
MX (1) MX2012001346A (cg-RX-API-DMAC7.html)
PE (1) PE20121643A1 (cg-RX-API-DMAC7.html)
SG (1) SG178119A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011014890A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201200716B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2521490T3 (es) 2006-12-15 2014-11-12 Baxter International Inc. Conjugado de factor VIIa - ácido (poli)siálico con una vida media in vivo prolongada.
SI3581650T1 (sl) 2008-09-15 2023-06-30 uniQuore biopharma B.V. Polipeptidni mutant faktorja IX, njegova uporaba in metoda za njegovo proizvodnjo
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5908401B2 (ja) 2009-07-27 2016-04-26 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 血液凝固タンパク質複合体
NZ597600A (en) 2009-07-27 2014-05-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
KR102269494B1 (ko) * 2010-07-30 2021-06-25 박스알타 인코퍼레이티드 옥심 결합용 친핵성 촉매
NZ612320A (en) 2010-12-22 2015-06-26 Baxter Healthcare Sa Materials and methods for conjugating a water soluble fatty acid derivative to a protein
CA2856492C (en) * 2011-12-19 2017-01-10 Dilafor Ab Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
BR112015011462A2 (pt) * 2012-11-20 2017-09-26 Univ North Carolina Chapel Hill processos e composições para proteínas fator ix modificadas
CN105121461A (zh) * 2013-03-13 2015-12-02 伊莱利利公司 修饰的犬瘦素多肽
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
CA3034566A1 (en) 2016-07-27 2018-02-01 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
EP3867380A2 (en) 2018-10-18 2021-08-25 Intellia Therapeutics, Inc. Compositions and methods for expressing factor ix

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1520259A (zh) * 2001-04-25 2004-08-11 ���ݴ�ѧУ��ίԱ�� 利用球状载体将第八因子/第九因子进行肝脏基因转移治疗血友病的方法
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
AU2004296860B2 (en) * 2003-12-03 2010-04-22 Novo Nordisk A/S Glycopegylated factor IX
EP2423305A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
CU20130057A7 (es) 2013-06-28
CL2012000238A1 (es) 2012-10-05
IN2012DN00908A (cg-RX-API-DMAC7.html) 2015-04-03
CU20130058A7 (es) 2013-06-28
AU2010278721A1 (en) 2012-02-16
CA2769258A1 (en) 2011-02-03
PE20121643A1 (es) 2012-11-25
US20120164130A1 (en) 2012-06-28
EA201290069A1 (ru) 2012-07-30
GT201200023A (es) 2014-01-27
MX2012001346A (es) 2012-02-17
ZA201200716B (en) 2013-07-31
EP2461821A1 (en) 2012-06-13
WO2011014890A1 (en) 2011-02-03
EP2461821A4 (en) 2013-07-03
CN102573890A (zh) 2012-07-11
ECSP12011637A (es) 2012-02-29
CU20120018A7 (es) 2012-06-21
BR112012002072A2 (pt) 2016-11-08
KR20120060209A (ko) 2012-06-11
SG178119A1 (en) 2012-03-29
JP2013500726A (ja) 2013-01-10
CR20120052A (es) 2012-06-04

Similar Documents

Publication Publication Date Title
DOP2012000030A (es) Polipéptidos del factor ix modificados y usos de los mismos
SV2010003704A (es) Polipeptidos modificados del factor ix y usos de los mismos
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CR20140512A (es) Dispositivos y metodos para la fabricación de aditivos de componentes de implante
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
HN2010000084A (es) Derivados de sulfonamida
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
MX2015011445A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
CO6501131A2 (es) Antagonistas de espiro-oxindol de mdm2
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
CR20140476A (es) Agentes para tratar transtornos que implican la modulación de receptores de rianodina
CR20150067A (es) Pirazoles sustituidos como bloqueadores del canal de calcio tipo n
ECSP109923A (es) Bromhidrato de bupropion y aplicaciones terapéuticas
MX2017014245A (es) Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas.
BR112013005855A2 (pt) heteroarilas fundidas e seus usos
UY34773A (es) Ácidos indanoiloxidihidrobenzofuranilacéticos como moduladores de la actividad de gpr40, composiciones que los contienen y sus usos
CR11631A (es) Paramyxovirus eficaz como antitumoral
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
CR20150070A (es) Pirrolopirazoles como bloqueadores del canal de calcio tipo n
UY33833A (es) Proteína de fusión Robo1-Fc para su uso en el tratamiento del hepatocarcinoma
BR112015010225A2 (pt) compostos tricíclicos e seus métodos de produção e utilização
BR112014031706A8 (pt) Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol
MX372807B (es) Copolimeros de bloque para proteccion del esmalte dental.
MX2016005227A (es) Polipéptidos de acción prolongada y métodos para su producción y administración.